Janux Therapeutics Reports Q3 Earnings Beat with $9.29 Million in Revenue
Janux Therapeutics (JANX) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.34, outperforming estimates by $0.14, while revenue reached $9.29 million, surpassing projections by $2.87 million despite a 7.1% year-over-year decline. The biotechnology firm maintains a robust liquidity position with $945.7 million in cash, cash equivalents, and short-term investments. This strong balance sheet is intended to fund the continued development of its various clinical-stage programs, including its ongoing research into prostate cancer treatments.
Tickers: $JANX
Topics: cash position clinical programs earnings beat revenue report